💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Supriya Lifescience Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs). The Company is primarily engaged in the manufacturing of bulk drugs and pharmaceutical chemicals. The Company exports its products in the antihistamine, anesthetics and…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, reasonably priced.
Supriya Lifescience is scored on the pharma / healthcare framework. It keeps a fat 24.9% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 0.89×). Free cash flow is worth about 0.2% of its market value.
Over the last 3 years revenue compounded at 21%/yr and profit at 33%/yr. Book value itself has compounded 20%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 17.5%. In the latest quarter profit fell 68% versus the prior quarter.
At 27× earnings, the stock sits at the 32nd percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price implies ~14%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 28.23 | — | — |
| P/B | 4.68 | 4.1 | worse |
| EV/EBITDA | 23.02 | 19.33 | worse |
| ROE | 17.46 | — | — |
| ROCE | 23 | 14.41 | better |
| ROA | 14.62 | — | — |
| Quick Ratio | 3.08 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 21% CAGR over 3 years — high-growth territory.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (33% vs 21%) — margin expansion is at work.
Operating margin has expanded from 26% to 33% — the business is keeping more of each rupee earned.
ROE at 17% — a respectable return on shareholder capital. ROE powered by fat margins — the hallmark of a high-quality franchise with pricing power.
EPS has grown every year — each share earns more than the last, consistently. 33% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 31% QoQ — could be seasonality or a genuine slowdown. Wide quarterly swings (31% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate stepping up — recent quarters average 15% above earlier ones.
Profit fell 68% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (25% → 12%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold 68.3% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.